The Sahajanand Medical Technologies IPO closes today, 19 October 2026, with bids accepted until the exchange cut-off. The issue is an offer for sale of up to 13,822,116 equity shares, worth about ₹475.48 crore at the price band of ₹327 to ₹344 a share, and the company will receive none of the proceeds because there is no fresh issue. The Surat-based maker of coronary stents and structural-heart devices plans to list on the BSE and NSE. This guide sets out the confirmed terms, the business behind the offer, and the risks worth reading before the window shuts.
Sahajanand Medical Technologies IPO: key takeaways
- Closes: Monday 19 October 2026; the prospectus gives 5:00 pm as the UPI mandate end time.
- Structure: 100% offer for sale; no fresh capital for the company.
- Price band: ₹327 to ₹344 per share, face value ₹1; lot size 43 shares.
- Tentative dates: allotment 21 October, refunds 22 October, listing 23 October.
- Business: vascular-intervention and structural-heart devices, including stents and TAVI devices.
Issue terms of the Sahajanand Medical Technologies IPO
According to the red herring prospectus dated 9 October 2026, the offer is a 100% book-built offer for sale, with the fresh issue marked not applicable. Anchor bidding took place on 14 October and the public issue opened on 15 October. Up to 250,000 shares are reserved for employees. Of the net offer, not more than 50% is for qualified institutional buyers, not less than 15% for non-institutional investors and not less than 35% for retail investors. At the upper band of ₹344, one lot of 43 shares costs ₹14,792, which is our multiplication. The book running lead managers are Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities and Capital Markets and Nuvama Wealth Management, and the registrar is MUFG Intime India.
Who is selling in the Sahajanand Medical Technologies IPO
Because every share on offer is sold by existing holders, the proceeds go to them. The prospectus names five selling shareholders: Shree Hari Trust (promoter), up to 2,700,000 shares; Dhirajkumar Savjibhai Vasoya (promoter group), 2,000,000; Samara Capital Markets Holding, 6,479,063; Kotak Pre-IPO Opportunities Fund, 1,307,875; and NHPEA Sparkle Holding B.V., 1,335,178. Those add up to the 13,822,116 shares in the offer. An offer for sale gives investors and promoters a partial exit and widens the shareholder base, but it does not fund expansion at the company.
Why the offer-for-sale structure matters
In a fresh issue, a company creates new shares and receives the money, which it can use for debt repayment, capacity or research. In an offer for sale, existing shareholders sell shares they already own, so the company’s balance sheet is unchanged by the proceeds. Buyers are therefore backing the existing business and its cash flows rather than a funded expansion plan. Listing still brings regulatory disclosure and share liquidity, which can matter to a company that wants to raise capital later.
The business behind the Sahajanand Medical Technologies IPO
Summaries of the offer documents describe a company incorporated in 2001 that makes devices for vascular and structural-heart interventions: coronary stents, balloons, transcatheter aortic valve implantation devices, occluders, renal stents and drug-coated balloons for peripheral arteries. Its brands include Supraflex Cruz, Cocoon and Hydra. The company is reported to run three manufacturing facilities across India and Thailand and two R&D centres, to hold 119 granted patents with 78 applications pending as of 30 June 2026, and to have sold products in 77 countries during FY26. Those figures come from offer-document summaries and the company’s website has more on the product range.
Financials reported for the Sahajanand Medical Technologies IPO
Restated figures reported from the offer documents put revenue from operations at ₹1,210.50 crore in FY26 against ₹1,024.88 crore in FY25, and profit after tax at ₹69.08 crore against ₹25.15 crore. By our arithmetic, that is revenue growth of about 18% and profit growth of about 175%, from a lower base. Total borrowings were reported at ₹269.53 crore against ₹224.96 crore. We have not audited these numbers, and readers should check them against the prospectus.
What happens after the issue closes
Once bidding ends, the exchanges and the registrar finalise subscription across the investor categories and determine the basis of allotment. The tentative schedule is allotment on 21 October, refunds of unallotted bids and credit of shares on 22 October, and listing on 23 October. Each of those dates is tentative and can change, so investors should watch the exchanges and the registrar for confirmation rather than rely on this timetable.
What we have not included
We have not reported live subscription figures, because they change through the day and must come from the exchanges’ bidding data; the offer documents page and the bidding pages on both exchanges are the places to check. We also leave out unofficial grey-market premiums, which are not a guide to listing performance.
Risks and caveats on the Sahajanand Medical Technologies IPO
- No fresh capital reaches the company, so the offer does not itself fund growth.
- Borrowings rose alongside profit in the reported figures.
- Coronary stents are a price-regulated category in India, which can limit margins.
- Listing dates are tentative and can change.
- This is news reporting, not investment advice.
In our assessment, the Sahajanand Medical Technologies IPO is a partial-exit offering from an established stent and structural-heart maker, so the questions for readers are valuation, borrowings and regulatory exposure rather than use of proceeds. See also South Africa Plans New Rules for Compounded Weight-Loss Drugs. More in our medical device coverage.
What to watch next on the Sahajanand Medical Technologies IPO
- Final subscription across investor categories after the close.
- The basis of allotment on 21 October.
- The listing on 23 October and early trading.
- Post-listing disclosures on growth and borrowings.
Frequently asked questions
When does the Sahajanand Medical Technologies IPO close?
Today, 19 October 2026.
What is the price band?
₹327 to ₹344 per share, with a lot size of 43 shares.
Does the company receive the money?
No. It is entirely an offer for sale, so proceeds go to the selling shareholders.
When is the listing?
Tentatively 23 October 2026, on the BSE and NSE.
How we reported this: we relied on the red herring prospectus dated 9 October 2026 and offer-document summaries for business and financial figures. Last updated: 19 October 2026. This article is news reporting and not investment advice.
